OncoMatch/Clinical Trials/NCT05863234
Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia
Is NCT05863234 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies PPMX-T003 for aggressive nk cell leukemia.
Treatment: PPMX-T003 — This is Phase I/II Dose-Escalation Study to evaluate the tolerability, safety, efficacy and pharmacokinetics of PPMX-T003 in aggressive NK-cell leukemia.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Lymphoblastic Leukemia
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05863234 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages